Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ATXS Astria Therapeutics	$6.85 +1.3%	$6.23	$3.56 ▼ $12.92	$381.50M	0.48	237,972 shs	406,491 shs
EVO Evotec	$3.76 -1.6%	$4.06	$2.84 ▼ $5.64	$1.36B	1.67	79,680 shs	43,215 shs
JANX Janux Therapeutics	$25.11 +0.6%	$24.61	$21.97 ▼ $71.71	$1.50B	2.86	895,949 shs	527,337 shs
SDGR Schrodinger	$19.38 -0.4%	$21.14	$16.60 ▼ $28.47	$1.43B	1.67	1.38 million shs	2.12 million shs

Analysts Agree—These Gold Picks Outshine the Rest

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ATXS Astria Therapeutics	+1.33%	+9.08%	+8.21%	+72.98%	-31.36%
EVO Evotec	-1.57%	-4.33%	-10.90%	-7.39%	+13.60%
JANX Janux Therapeutics	+0.56%	+9.99%	-7.00%	+3.42%	-37.49%
SDGR Schrodinger	-0.36%	+0.88%	-8.80%	-17.81%	+2.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ATXS Astria Therapeutics	2.7119 of 5 stars	3.6	3.0	3.3	1.7	0.0
EVO Evotec	1.784 of 5 stars	3.3	2.0	2.4	0.0	0.6
JANX Janux Therapeutics	2.4023 of 5 stars	3.5	3.0	2.3	1.7	0.0
SDGR Schrodinger	3.2074 of 5 stars	3.3	3.0	3.0	3.3	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ATXS Astria Therapeutics	3.14	Buy	$29.00	323.36% Upside
EVO Evotec	2.50	Moderate Buy	$5.40	43.62% Upside
JANX Janux Therapeutics	3.08	Buy	$91.89	265.95% Upside
SDGR Schrodinger	2.67	Moderate Buy	$29.33	51.36% Upside

Current Analyst Ratings Breakdown

Latest ATXS, SDGR, EVO, and JANX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/15/2025	SDGR Schrodinger	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral	$35.00 ➝ $20.00
8/14/2025	EVO Evotec	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$8.00 ➝ $7.00
8/14/2025	SDGR Schrodinger	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$25.00
8/14/2025	SDGR Schrodinger	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$25.00
8/13/2025	ATXS Astria Therapeutics	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform
8/13/2025	ATXS Astria Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Market Outperform ➝ Market Outperform	$25.00 ➝ $26.00
8/13/2025	ATXS Astria Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$16.00
7/14/2025	SDGR Schrodinger	KeyCorp Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$32.00 ➝ $30.00
7/11/2025	JANX Janux Therapeutics	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$65.00
7/3/2025	SDGR Schrodinger	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Equal Weight	$28.00
6/13/2025	ATXS Astria Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$16.00

(Data available from 8/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ATXS Astria Therapeutics	N/A	N/A	N/A	N/A	$2.93 per share	N/A
EVO Evotec	$862.40M	1.55	N/A	N/A	$2.70 per share	1.39
JANX Janux Therapeutics	$10.59M	142.48	N/A	N/A	$16.48 per share	1.52
SDGR Schrodinger	$207.54M	6.85	N/A	N/A	$4.67 per share	4.15

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ATXS Astria Therapeutics	-$94.26M	-$2.01	N/A	N/A	N/A	N/A	-56.39%	-36.08%	N/A
EVO Evotec	-$212.18M	N/A	0.00	N/A	N/A	-20.14%	-16.94%	-8.14%	N/A
JANX Janux Therapeutics	-$68.99M	-$1.80	N/A	N/A	N/A	N/A	-11.48%	-11.01%	N/A
SDGR Schrodinger	-$187.12M	-$2.48	N/A	N/A	N/A	-76.22%	-45.70%	-24.81%	N/A

Latest ATXS, SDGR, EVO, and JANX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2025	Q2 2025	ATXS Astria Therapeutics	-$0.61	-$0.57	+$0.04	-$0.57	$16.00 million	N/A
8/7/2025	Q2 2025	JANX Janux Therapeutics	-$0.48	-$0.55	-$0.07	-$0.55	$0.30 million	N/A
8/6/2025	Q2 2025	SDGR Schrodinger	-$0.83	-$0.59	+$0.24	-$0.59	$52.03 million	$54.76 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ATXS Astria Therapeutics	N/A	N/A	N/A	N/A	N/A
EVO Evotec	N/A	N/A	N/A	N/A	N/A
JANX Janux Therapeutics	N/A	N/A	N/A	N/A	N/A
SDGR Schrodinger	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ATXS Astria Therapeutics	N/A	14.89	17.39
EVO Evotec	0.42	1.58	1.93
JANX Janux Therapeutics	N/A	47.03	47.03
SDGR Schrodinger	N/A	3.30	3.30

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ATXS Astria Therapeutics	98.98%
EVO Evotec	5.81%
JANX Janux Therapeutics	75.39%
SDGR Schrodinger	79.05%

Insider Ownership

Company	Insider Ownership
ATXS Astria Therapeutics	4.50%
EVO Evotec	1.00%
JANX Janux Therapeutics	8.10%
SDGR Schrodinger	21.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ATXS Astria Therapeutics	30	56.44 million	53.90 million	Optionable
EVO Evotec	4,827	355.11 million	351.56 million	Not Optionable
JANX Janux Therapeutics	30	60.09 million	55.23 million	Optionable
SDGR Schrodinger	790	73.38 million	57.97 million	Optionable

ATXS, SDGR, EVO, and JANX Headlines

Recent News About These Companies

Schrodinger (NASDAQ:SDGR) Sets New 12-Month Low - Here's What Happened

4 hours ago | marketbeat.com

Schrodinger downgraded at Citi after clinical program exit

August 16 at 3:38 AM | msn.com

Citigroup Downgrades Schrödinger (SDGR)

August 16 at 3:38 AM | msn.com

Schrodinger, Inc. (NASDAQ:SDGR) Given Consensus Recommendation of "Moderate Buy" by Brokerages

August 16 at 3:22 AM | marketbeat.com

Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

August 15 at 4:30 PM | businesswire.com

Barclays Initiates Coverage of Schrödinger (SDGR) with Overweight Recommendation

August 15 at 3:48 AM | msn.com

Schrodinger downgraded to Neutral from Buy at Citi

August 15 at 3:48 AM | msn.com

Schrödinger Discontinues Clinical Program After Two Patient Deaths

August 14 at 10:47 PM | msn.com

Schrödinger Halts Cancer Drug Program after Two Patients Die in Phase I Trial

August 14 at 5:41 PM | genengnews.comG

Schrodinger discontinues SGR-2921 clinical development program

August 14 at 12:40 PM | msn.com

Schrodinger stock plunges after discontinuing key leukemia drug

August 14 at 12:40 PM | investing.com

Schrödinger stops development of blood cancer therapy after two patient deaths

August 14 at 12:40 PM | reuters.com

Schrödinger Stock Plummets After Halting Key Leukemia Drug Program

August 14 at 12:40 PM | msn.com

Schrödinger Announces Discontinuation of SGR-2921 Program

August 14 at 7:38 AM | finance.yahoo.com

Leerink Partnrs Forecasts Increased Earnings for Schrodinger

August 12, 2025 | americanbankingnews.com

Schrodinger (SDGR) Receives a Buy from Citi

August 11, 2025 | theglobeandmail.com

Schrodinger, Inc. Earnings Call: Growth Amid Challenges

August 11, 2025 | theglobeandmail.com

Schrodinger (SDGR) Gets a Buy from Craig-Hallum

August 11, 2025 | theglobeandmail.com

Leerink Partnrs Lifts Earnings Estimates for Schrodinger

August 11, 2025 | marketbeat.com

SchrÃ¶dinger, Inc. (SDGR) Q2 2025 Earnings Call Transcript

August 6, 2025 | seekingalpha.com

Schrödinger, Inc. 2025 Q2 - Results - Earnings Call Presentation

August 6, 2025 | seekingalpha.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

ATXS, SDGR, EVO, and JANX Company Descriptions

Astria Therapeutics NASDAQ:ATXS

$6.85 +0.09 (+1.33%)

Closing price 08/15/2025 04:00 PM Eastern

Extended Trading

$7.00 +0.15 (+2.20%)

As of 08/15/2025 04:50 PM Eastern

Astria Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema. The company is also developing STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, an immune disorder associated with loss of skin barrier function and itching. The company was formerly known as Catabasis Pharmaceuticals, Inc. and changed its name to Astria Therapeutics, Inc. in September 2021. Astria Therapeutics, Inc. was incorporated in 2008 and is headquartered in Boston, Massachusetts.

Evotec NASDAQ:EVO

$3.76 -0.06 (-1.57%)

Closing price 08/15/2025 04:00 PM Eastern

Extended Trading

$3.75 -0.01 (-0.27%)

As of 08/15/2025 07:39 PM Eastern

Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as autoimmune diseases, cancer, CNS diseases, diabetes, fibrosis, immunology, infectious diseases, kidney diseases, liver diseases, pain and inflammation, rare diseases, respiratory diseases, tuberculosis, and women's health. It has collaboration agreements with SK bioscience, JingXin, Carrick Therapeutics, Sernova, Topas Therapeutics, Exscientia, CONBA Group, Centrexion, Sanofi/NIH, Kazia Therapeutics, Bristol Myers Squibb, Topas Therapeutics, Immunitas, Exscientia, and Bayer; and Inserm, the French National Institute of Health and Medical Research, Lille University Hospital, and Inserm Transfert to identify novel therapeutic targets and diagnostic and prognostic markers in obesity and metabolic diseases, as well as collaboration with CHDI Foundation, Inc.; and a strategic partnership with Dewpoint Therapeutics to advance its portfolio targeting biomolecular condensates as a novel domain for therapeutic intervention towards the clinic, as well as research collaboration with Pfizer for metabolic and infectious diseases. The company was formerly known as Evotec AG and changed its name to Evotec SE in April 2019. Evotec SE was incorporated in 1993 and is headquartered in Hamburg, Germany.

Janux Therapeutics NASDAQ:JANX

$25.11 +0.14 (+0.56%)

Closing price 08/15/2025 04:00 PM Eastern

Extended Trading

$25.12 +0.02 (+0.06%)

As of 08/15/2025 04:34 PM Eastern

Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma. Its development pipeline also consists of discovery stage products. The company has strategic research collaboration agreement with Merck Sharp & Dohme Corp. to develop TRACTr product candidates. Janux Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.

Schrodinger NASDAQ:SDGR

$19.38 -0.07 (-0.36%)

Closing price 08/15/2025 04:00 PM Eastern

Extended Trading

$19.50 +0.13 (+0.64%)

As of 08/15/2025 07:59 PM Eastern

Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on licensing its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. The company serves biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time